Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Payables (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Payables data on record, last reported at $1.1 million in Q4 2025.

  • For Q4 2025, Payables rose 86.55% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, up 86.55%, while the annual FY2025 figure was $1.4 million, 15.1% down from the prior year.
  • Payables reached $1.1 million in Q4 2025 per INM's latest filing, up from $369088.0 in the prior quarter.
  • Across five years, Payables topped out at $2.9 million in Q1 2022 and bottomed at $369088.0 in Q3 2025.
  • Average Payables over 5 years is $1.4 million, with a median of $1.2 million recorded in 2022.
  • The widest YoY moves for Payables: up 86.55% in 2025, down 63.52% in 2025.
  • A 5-year view of Payables shows it stood at $2.1 million in 2021, then plummeted by 41.62% to $1.2 million in 2022, then rose by 3.08% to $1.3 million in 2023, then plummeted by 55.38% to $574563.0 in 2024, then surged by 86.55% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $1.1 million in Q4 2025, $369088.0 in Q3 2025, and $1.4 million in Q2 2025.